These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18607693)

  • 1. Effect of ethylenediamine on chemical degradation of insulin aspart in pharmaceutical solutions.
    Poulsen C; Jacobsen D; Palm L
    Pharm Res; 2008 Nov; 25(11):2534-44. PubMed ID: 18607693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature.
    Teska BM; Alarcón J; Pettis RJ; Randolph TW; Carpenter JF
    J Pharm Sci; 2014 Aug; 103(8):2255-67. PubMed ID: 24909933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin aspart (AspB28 human insulin) derivatives formed in pharmaceutical solutions.
    Jars MU; Hvass A; Waaben D
    Pharm Res; 2002 May; 19(5):621-8. PubMed ID: 12069164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.
    Havelund S; Ribel U; Hubálek F; Hoeg-Jensen T; Wahlund PO; Jonassen I
    Pharm Res; 2015 Jul; 32(7):2250-8. PubMed ID: 25563978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
    Gast K; Schüler A; Wolff M; Thalhammer A; Berchtold H; Nagel N; Lenherr G; Hauck G; Seckler R
    Pharm Res; 2017 Nov; 34(11):2270-2286. PubMed ID: 28762200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump.
    Senstius J; Harboe E; Westermann H
    Diabetes Technol Ther; 2007 Feb; 9(1):75-9. PubMed ID: 17316101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin aspart: a new rapid-acting insulin analog.
    Setter SM; Corbett CF; Campbell RK; White JR
    Ann Pharmacother; 2000 Dec; 34(12):1423-31. PubMed ID: 11144701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic fibrillation of fast-acting insulin analogs.
    Woods RJ; Alarcón J; McVey E; Pettis RJ
    J Diabetes Sci Technol; 2012 Mar; 6(2):265-76. PubMed ID: 22538135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and identification of high molecular weight products formed during storage of neutral formulation of human insulin.
    Hjorth CF; Hubálek F; Andersson J; Poulsen C; Otzen D; Naver H
    Pharm Res; 2015 Jun; 32(6):2072-85. PubMed ID: 25583030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps.
    Senstius J; Poulsen C; Hvass A
    Diabetes Technol Ther; 2007 Dec; 9(6):517-21. PubMed ID: 18034606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of N-Terminally Truncated Derivatives of Insulin Analogs Formed in Pharmaceutical Formulations.
    Zielińska J; Stadnik J; Bierczyńska-Krzysik A; Stadnik D
    Pharm Res; 2018 May; 35(7):143. PubMed ID: 29770892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USAN Council. List No.417. New names. Insulin Aspart.
    Clin Pharmacol Ther; 1999 Jul; 66(1):103. PubMed ID: 10447384
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimising insulin aspart practices in a neonatal intensive care unit: a clinical and pharmaco-technical study.
    Préta LH; Genay S; Malat C; Carta N; Boukhris MR; Verspieren J; Odou P; Storme L; Décaudin B
    Eur J Pediatr; 2021 Sep; 180(9):2985-2992. PubMed ID: 33866404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
    Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
    Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
    Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS
    Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
    Bode BW
    Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes.
    Raja-Khan N; Warehime SS; Gabbay RA
    Vasc Health Risk Manag; 2007; 3(6):919-35. PubMed ID: 18200811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin aspart.
    Simpson KL; Spencer CM
    Drugs; 1999 May; 57(5):759-65; discussion 766-7. PubMed ID: 10353301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucoadhesive polyelectrolyte microparticles containing recombinant human insulin and its analogs aspart and lispro.
    Balabushevich NG; Pechenkin MA; Zorov IN; Shibanova ED; Larionova NI
    Biochemistry (Mosc); 2011 Mar; 76(3):327-31. PubMed ID: 21568867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.